Prescriber Adoption of SLCO1B1 Genotype-Guided Simvastatin Clinical Decision Support in a Clinical Pharmacogenetics Program.
Journal
Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
15
08
2022
accepted:
08
10
2022
pubmed:
15
11
2022
medline:
27
1
2023
entrez:
14
11
2022
Statut:
ppublish
Résumé
Pharmacogenetic implementation programs are increasingly feasible due to the availability of clinical guidelines for implementation research. The utilization of these resources has been reported with selected drug-gene pairs; however, little is known about how prescribers respond to pharmacogenetic recommendations for statin therapy. We prospectively assessed prescriber interaction with point-of-care clinical decision support (CDS) to guide simvastatin therapy for a diverse cohort of primary care patients enrolled in a clinical pharmacogenetics program. Of the 1,639 preemptively genotyped patients, 298 (18.2%) had an intermediate function (IF) OATP1B1 phenotype and 25 (1.53%) had a poor function (PF) phenotype, predicted by a common single nucleotide variant in the SLCO1B1 gene (c.521T>C; rs4149056). Clinicians were presented with CDS when simvastatin was prescribed for patients with IF or PF through the electronic health record. Importantly, 64.2% of the CDS deployed at the point-of-care was accepted by the prescribers and resulted in prescription changes. Statin intensity was found to significantly influence prescriber adoption of the pharmacogenetic-guided CDS, whereas patient gender or race, prescriber type, or pharmacogenetic training status did not significantly influence adoption. This study demonstrates that primary care providers readily adopt pharmacogenetic information to guide statin therapy for the majority of patients with preemptive genotype data.
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Simvastatin
AGG2FN16EV
SLCO1B1 protein, human
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
321-327Subventions
Organisme : NIH HHS
ID : U01HG006380
Pays : United States
Informations de copyright
© 2022 The Authors. Clinical Pharmacology & Therapeutics © 2022 American Society for Clinical Pharmacology and Therapeutics.
Références
Stanek, E.J. et al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin. Pharmacol. Ther. 91(3), 450-458 (2012).
Empey, P.E. et al. Multisite investigation of strategies for the implementation of CYP2C19 genotype-guided antiplatelet therapy. Clin. Pharmacol. Ther. 104(4), 664-674 (2018).
Duarte, J.D. et al. Multisite investigation of strategies for the clinical implementation of pre-emptive pharmacogenetic testing. Genet. Med. 23(12), 2335-2341 (2021).
Relling, M.V. & Klein, T.E. CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin. Pharmacol. Ther. 89(3), 464-467 (2011).
McCarty, C.A. et al. The eMERGE Network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies. BMC Med. Genomics 4, 13 (2011).
Pulley, J.M. et al. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin. Pharmacol. Ther. 92(1), 87-95 (2012).
Gottesman, O. et al. The CLIPMERGE PGx Program: clinical implementation of personalized medicine through electronic health records and genomics-pharmacogenomics. Clin. Pharmacol. Ther. 94(2), 214-217 (2013).
Smith, D.M. et al. CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial. Genet. Med. 21(8), 1842-1850 (2019).
Pinna, M. et al. Protocol for a pharmacogenetic study of antidepressants: characterization of drug-metabolizing profiles of cytochromes CYP2D6 and CYP2C19 in a Sardinian population of patients with major depressive disorder. Psychiatr. Genet. 31(5), 186-193 (2021).
Peterson, J.F. et al. Physician response to implementation of genotype-tailored antiplatelet therapy. Clin. Pharmacol. Ther. 100(1), 67-74 (2016).
Arnett, D.K. et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation 140(11), e596-e646 (2019).
du Souich, P., Roederer, G. & Dufour, R. Myotoxicity of statins: mechanism of action. Pharmacol. Ther. 175, 1-16 (2017).
Hope, H.F., Binkley, G.M., Fenton, S., Kitas, G.D., Verstappen, S.M.M. & Symmons, D.P.M. Systematic review of the predictors of statin adherence for the primary prevention of cardiovascular disease. PLoS One 14(1), e0201196 (2019).
Ju, A. et al. Patient beliefs and attitudes to taking statins: systematic review of qualitative studies. Br. J. Gen. Pract. 68(671), e408-e419 (2018).
Nguyen, K.A. et al. A comprehensive review and meta-analysis of risk factors for statin-induced myopathy. Eur. J. Clin. Pharmacol. 74(9), 1099-1109 (2018).
Ward, N.C., Watts, G.F. & Eckel, R.H. Statin toxicity. Circ. Res. 124(2), 328-350 (2019).
Link, E. et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N. Engl. J. Med. 359(8), 789-799 (2008).
Xiang, Q. et al. Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis. Pharmacogenomics J. 18(6), 721-729 (2018).
Cooper-DeHoff, R.M. et al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms. Clin. Pharmacol. Ther. 111(5), 1007-1021 (2022).
Vassy, J.L. et al. Effect of pharmacogenetic testing for statin myopathy risk vs usual care on blood cholesterol: a randomized clinical trial. JAMA Netw. Open 3(12), e2027092 (2020).
Wilke, R.A. et al. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin. Pharmacol. Ther. 92(1), 112-117 (2012).
Larson, E.A. & Wilke, R.A. Integration of genomics in primary care. Am. J. Med. 128(11), 1251.e1-5 (2015).
Rasmussen-Torvik, L.J. et al. Design and anticipated outcomes of the eMERGE-PGx project: a multicenter pilot for preemptive pharmacogenomics in electronic health record systems. Clin. Pharmacol. Ther. 96(4), 482-489 (2014).
Grundy, S.M. et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation 139(25), e1082-e1143 (2019).
Overby, C.L. et al. Physician attitudes toward adopting genome-guided prescribing through clinical decision support. J Pers Med. 4(1), 35-49 (2014).
Weitzel, K.W. et al. Clinical pharmacogenetics implementation: approaches, successes, and challenges. Am. J. Med. Genet. C Semin. Med. Genet. 166C(1), 56-67 (2014).
Lee, J.A. et al. Implementation and evaluation of a CYP2C19 genotype-guided antiplatelet therapy algorithm in high-risk coronary artery disease patients. Pharmacogenomics 16(4), 303-313 (2015).
Dodson, C. Knowledge and attitudes concerning pharmacogenomics among healthcare professionals. Per Med. 8(4), 421-428 (2011).
Johansen Taber, K.A. & Dickinson, B.D. Pharmacogenomic knowledge gaps and educational resource needs among physicians in selected specialties. Pharmgenomics Pers Med. 7, 145-162 (2014).
Rahawi, S. et al. Knowledge and attitudes on pharmacogenetics among pediatricians. J. Hum. Genet. 65(5), 437-444 (2020).
Rigobello, R. et al. Clinical pharmacogenetic testing and the posttest counseling conundrum. Clin. Pharmacol. Ther. 108(5), 924-928 (2020).